Skip to main content
Clinical Trials/NCT01436825
NCT01436825CompletedNot Applicable

A Validation Study of the OPTIMS Pharmacokinetic Calculator for Clinician Use in Prophylactic Treatment of Patients With Haemophilia A.

Bayer0 sites69 target enrollmentStarted: October 2011Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Bayer
Enrollment
69
Primary Endpoint
The difference of the recovery rate calculated by the physician and the recovery rate calculated by an independent calculator With OPTIMS Tool

Study Overview

Brief Summary

OPTIMS is a non interventional validation study of the calculator developed by Bayer for clinician's use in the prophylactic treatment by factor VIII of patients with severe or moderate Haemophilia A with a severe clinical profile.

The study takes place during a single visit, at the time of patient enrollment in the study

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patient with severe haemophilia A defined as residual factor VIII activity < 1%
  • or Patient with moderate haemophilia A (residual factor VIII activity >1% and <5%) with severe clinical profile
  • Patient treated in prevention with the same plasma or recombinant factor VIII for at least 6 months
  • Patient whose inclusion visit is performed during a routine visit including a measurement of plasma residual factor VIII :c level
  • In the medical file (retrospective data) the pharmacokinetic parameters are available and have been obtained from a PK analysis of factor VIII level performed with the same anti haemophilic factor than the one used on the inclusion day

Exclusion Criteria

  • Patients with haemophilia B

Arms & Interventions

Group 1

Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222) (Drug)

Outcomes

Primary Outcomes

The difference of the recovery rate calculated by the physician and the recovery rate calculated by an independent calculator With OPTIMS Tool

Time Frame: after 1 month

The difference of the elimination half-life calculated by the physician and the ones calculated by an independent calculator With OPTIMS Tool

Time Frame: after 1 month

The difference of the clearance calculated by the physician and the ones calculated by an independent calculator With OPTIMS Tool

Time Frame: after 1 month

Secondary Outcomes

  • The dosage of factor VIII calculated by OPTIMS calculator(within 48 hours after enrollment)
  • The practicality of the OPTIMS calculator by a physician's satisfaction questionnaire(within 48 hours after enrollment)

Investigators

Sponsor
Bayer
Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Completed
Not Applicable
Observational study to evaluate pharmacokinetics and pharmacodynamics of docetaxel, paclitaxel, doxorubicin, gemcitabine, vinorelbine, and capecitabine in elderly patients.cancer malignancies10027655
NL-OMON47924Antoni van Leeuwenhoek Ziekenhuis337
Active, not recruiting
Not Applicable
Study to evaluate the efficacy, metabolism and safety of human immuneglobulin in patients with primary immunodeficiency diseasesprimary immunodeficiency disease (PID)MedDRA version: 14.1Level: LLTClassification code 10049485Term: Bruton's agammaglobulinemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencySystem Organ Class: 10021428 - Immune system disorders
EUCTR2012-000792-16-HUOCTAPHARMA AG23
Active, not recruiting
Not Applicable
Study to evaluate the efficacy, metabolism and safety of human immuneglobulin in patients with primary immunodeficiency diseasesprimary immunodeficiency disease (PID)MedDRA version: 14.1Level: LLTClassification code 10049485Term: Bruton's agammaglobulinemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10010112Term: Common variable immunodeficiencySystem Organ Class: 10021428 - Immune system disorders
EUCTR2012-000792-16-CZOCTAPHARMA AG23
Active, not recruiting
Not Applicable
Study to evaluate the efficacy, metabolism and safety of human immuneglobulin in patients with primary immunodeficiency diseases
EUCTR2012-000792-16-DEOCTAPHARMA AG23
Recruiting
Not Applicable
Validation of Pharmacokinetic and Pharmacodynamic Assays for determination of Nivolumab and Pembrolizumab concentrations, and the occupancy of their target receptor Programmed Death-1 (PD-1) on T-cellsmetastasized cancerSolid tumors10027476
NL-OMON47401Antoni van Leeuwenhoek Ziekenhuis70